Skip to main content

Table 2 Study outcomes

From: Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial

Outcome Total N = 229 CLARITHRO n = 6127% CIPRO n = 5624% METRO n = 5725% CIPRO-Plus n = 5524% p-value1
Treatment failure (Positive FAT) (%) Total group (n = 85) 20 13 18 36 12 0.191
No prior exposure to triple therapy (n = 73) 22 14 21 39 14 0.265
HRQoLin total group (mean ± SD) Score after treatment 32 ± 11 31 ± 10 31 ± 10 36 ± 12** 31 ± 9 0.023
Mean difference 44 ± 14 46 ± 15 44 ± 15 40 ± 13* 47 ± 13 0.032
HRQoL in functional dyspepsia (n = 37) (mean ± SD) Score after treatment 30 ± 9 33 ± 13 28 ± 7 32 ± 6 24 ± 5 0.229
Mean difference 42 ± 15 38 ± 17 42 ± 17 42 ± 10 51 ± 16 0.392
Persistence of symptoms (%) Total group (n = 229) 22 18 23 26 20 0.715
No prior exposure to triple therapy (n = 189) 23 19 26 29 18 0.492
  1. *P-value by multiple regression for comparison to the reference group (CLARITHRO), *P ≤ 0.05, **P ≤ 0.01
  2. 1Student t-test or chi square test as appropriate